Robert Malone on Biodefense Bureaucracies… power, fear, and genuine threats

Dr. Robert Malone, a physician-scientist with deep expertise in biodefense, laid bare the inefficiencies, corruption, and political maneuvering embedded in U.S. agencies responsible for pandemic preparedness and biodefense.

From the labyrinthine contracts of BARDA (Biomedical Advanced Research and Development Authority) [a subdivision of both HHS and ASPR (Administration for Strategic Preparedness and Response) to the unchecked power of the Senior Executive Service (SES), Malone detailed a system riddled with flaws — while warning that genuine threats from bad actors like Iran and China persist.

Key Observations

(1)  Real Bioweapon Dangers
While critiquing the inefficiencies of biodefense agencies, Malone emphasized that genuine threats remain. Iran’s instability and China’s capabilities make the development of bioweapons a real and urgent concern. He also noted the long history of biowarfare, from Soviet defectors revealing anthrax programs to World War II experiments by Japan. “There are bad guys in the world,” he said, “and bioweapons have always been part of their arsenal.”

(2)  Origins of Biodefense Agencies
BARDA: created post-9/11 to address bioterrorism fears, was a product of Dick Cheney’s concern about smallpox being weaponized. However, as these agencies grew, Malone argued, they became less about defense and more about sustaining budgets and political influence.

(3)  Fear as a Business Model
Malone described the ecosystem as one driven by “psychological bioterrorism.” Hypothetical threats, such as bird flu — which the CDC itself stated is not an imminent danger — are hyped to justify funding. “You can gin up fear around any potential threat,” Malone said, “and turn it into a billion-dollar initiative.”

(4)  Structural Inefficiencies
Agencies like NIH, BARDA, and ASPR often clash over jurisdiction, creating years-long delays. Malone described the process as “cheese wars,” with agencies fighting over budgets and control. This inefficiency is compounded by federal acquisition regulations (FAR), which make government contracting cumbersome and unappealing to innovative companies.

(5)  The Role of OTAs
The introduction of Other Transaction Authorities (OTAs) was meant to bypass FAR’s red tape. However, Malone explained that OTAs were misused during Operation Warp Speed, allowing unregulated procurement of millions of vaccine doses. “OTAs are supposed to develop prototypes,” he said. “Not fund mass production.”

(6)  The Senior Executive Service (SES) Problem
Malone described the SES as the administrative state’s backbone — an entrenched group of unelected bureaucrats who effectively run government agencies. With protections against dismissal, they wield immense power and resist change. “These people are immune to accountability,” Malone argued, likening their influence to that of medieval dukes and duchesses.

(7)  Challenges of Public-Private Partnerships
Biodefense products, unlike commercial goods, have no market outside government contracts. Developing vaccines for non-circulating diseases requires government sponsorship, which Malone likened to corporatism. “The taxpayer funds the research, then pays again when the product is sold back to the government at a profit,” he said.

(8)  Genuine Need for Biodefense
Despite its flaws, the biodefense ecosystem is necessary. Malone pointed out that treaties like the Bioweapons Convention are full of loopholes, permitting “non-lethal” incapacitating agents. Countries like Israel, which didn’t sign the treaty, are under no restrictions, and non-state actors remain a wildcard. “The threat is real,” Malone warned, “but the system we have isn’t agile enough to address it effectively.”

(9)  Proposed Reforms
Malone outlined potential solutions to reform the bureaucracy:

• • Decentralizing agencies like NIH and BARDA to reduce mission creep.
  • Introducing term limits for SES members to dismantle their stranglehold on power.
  • Creating hybrid private-public entities to mimic the efficiency of the private sector while maintaining public oversight.
  • Focusing government efforts on health promotion rather than solely treating diseases.

The Business Model Problem
Preparing vaccines for hypothetical threats — like smallpox or tularemia — is inherently difficult. Malone noted that the current system incentivizes waste and redundancy, as manufacturers rely on government contracts to survive. “There’s no private-sector analog,” he admitted. “The market is artificial, and that makes reform extraordinarily difficult.”

Top Quotes

1. “There are bad guys in the world, and there is a long, rich history of biowarfare that goes back centuries.”
2. “BARDA is a cash cow—a fantastic business model where you produce something that nobody really uses, you hope that they never use it, and it gets purchased in a large single purchase by a single purchaser.”
3. “I call it psychological bioterrorism: fear-mongering over us, the people.”
4. “The government’s cheese wars—agencies fighting over, ‘this is my cheese, not your cheese.’”
5. “OTAs were supposed to enable innovation but ended up being misused to yield millions and millions of doses of an experimental product.”
6. “The Senior Executive Service is the administrative state—they are permanent employees. Presidents come and go; they stay.”
7. “You, as a taxpayer, pay for a company to develop a product and file patents, which it then sells to you at a profit. That’s the ecosystem.”
8. “The Bioweapons Treaty is Swiss cheese—it is full of holes, and one of the most notorious is that it is not binding on non-lethal biowarfare agents.”
9. “If we stop disease before it ever develops, then we don’t need all the therapeutics and prophylactics.”
10. “The current system is stuck in an artificial market where the government has to create a customer for products that otherwise would have no market.”

Join us on weekdays at 5 pm ET weekdays on America Out Loud Talk Radio. Listen on iHeart Radio, our world-class media player, or our free apps on Apple, Android, or Alexa. Discover all the episodes on podcast networks, i.e., Apple Podcasts, Spotify, Pandora, TuneIn, Stitcher, and iHeart. You’ll find them the day after they air on talk radio, available on podcast. Extraordinary voices for extraordinary times.